Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
RESEARCH TRIANGLE PARK, N.C., March 12, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced the closing of an underwritten public...
-
RESEARCH TRIANGLE PARK, N.C., March 07, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced the pricing of an underwritten public...
-
RESEARCH TRIANGLE PARK, N.C., March 05, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced that it has commenced an underwritten public...
-
Statistically significant results highlight benefit of trilaciclib in several prospectively-defined parameters, including: Grade 4 neutropenia, G-CSF usage, and chemotherapy dose reductions and...
-
RESEARCH TRIANGLE PARK, N.C., March 01, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark Velleca,...
-
Topline data expected in March 2018 from first of three ongoing Phase 2 trials evaluating the myelopreservation benefits of trilaciclib Management to host webcast and conference call today at 4:30...
-
RESEARCH TRIANGLE PARK, N.C., Feb. 14, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced that fourth quarter and full-year 2017...
-
RESEARCH TRIANGLE PARK, N.C., Jan. 02, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark Velleca,...
-
RESEARCH TRIANGLE PARK, N.C., Dec. 18, 2017 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced that it has been selected for addition to the...
-
RESEARCH TRIANGLE PARK, N.C., Dec. 06, 2017 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced the grant of an equity inducement award to...